Paul Thomen

Friday, 9 May 2014

Japan Neuropathic Pain Drug Market Growth Prospects and Developments to 2022



The Report “PharmaPoint: Neuropathic Pain – Japan Drug Forecast and Market Analysis to 2022″ by Globaldata Group is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com  with “PharmaPoint: Neuropathic Pain – Japan Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.
Similar to the rest of the global markets, this will be fueled predominantly by the growing incidence of NP as a result of the increasing elderly population, which is even more pronounced in Japan. However, unlike the other countries in the 7MM, most of the growth in the NP market in Japan will not be due to the entry of numerous pipeline drugs, but rather will be the result of the delayed launch and continued growth of both Lyrica and Cymbalta. Both these drugs launched in Japan approximately five years after their launch in the US and EU. Furthermore, both drugs are subject to extended exclusivity in Japan, with the patent for Lyrica not set to expire in Japan until 2022, and the post-marketing exclusivity for Cymbalta estimated to extend to 2017.
 Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=173904 .
Scope
§  Overview of Neuropathic Pain including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
§  Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
§  Sales forecast for the top drugs in Japan from 2012-2022.
§  Analysis of the impact of key events as well the drivers and restraints affecting the Japan Neuropathic Pain market.
Reasons to buy
§  Understand and capitalize by identifying products that are most likely to ensure a robust return
§  Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic Pain.
§  Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
§  Make more informed business decisions from insightful and in-depth analysis of drug performance
§  Obtain sales forecast for drugs from 2012-2022 in Japan.


Table of Contents

1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 12
3 Disease Overview 14
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 16
3.1.1 Painful Diabetic Neuropathy 18
3.1.2 Postherpetic Neuralgia 19
3.1.3 Trigeminal Neuralgia 19
3.2 Etiology and Pathophysiology 20
3.2.1 Etiology 21
3.2.2 Pathophysiology 22
4 Disease Management 30
4.1 Diagnosis and Treatment Overview 30

For further information on “PharmaPoint: Neuropathic Pain – Japan Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘pharmaceuticals’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ), contact sales@rnrmarketresearch.com   / Call +1 888 391 5441.

About Us:
RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

You can also reach us @

No comments:

Post a Comment

Note: only a member of this blog may post a comment.